Cumberbatch M J, Hill R G, Hargreaves R J
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Center, Harlow, Essex, UK.
Eur J Pharmacol. 1998 Nov 27;362(1):43-6. doi: 10.1016/s0014-2999(98)00764-x.
Pre-clinical studies have suggested that one mechanism of antimigraine action of the 'triptan' 5-HT1B/1D receptor agonists may be through inhibition of central nociceptive transmission in the trigeminal dorsal horn. In anaesthetized rats, the 5-HT1B/1D receptor agonist, zolmitriptan (up to 3 mg kg(-1), i.v.), inhibited the action potential discharge of single trigeminal neurones to noxious electrical stimulation of the middle meningeal artery. In contrast, the selective 5-HT1B receptor agonist, CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one), and the 5-HT1A receptor selective agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) had no effect in this assay at up to 3 mg kg(-1), i.v.. Brain penetrant, triptan 5-HT1B/1D receptor agonists may therefore mediate their central trigeminal anti-nociceptive action in the rat via 5-HT1D, but not 5-HT1B or 5-HT1A, receptors.
临床前研究表明,“曲坦类”5-HT1B/1D受体激动剂的抗偏头痛作用机制之一可能是通过抑制三叉神经背角的中枢伤害性传递。在麻醉大鼠中,5-HT1B/1D受体激动剂佐米曲坦(静脉注射,剂量高达3 mg kg(-1))可抑制三叉神经单个神经元对脑膜中动脉有害电刺激的动作电位发放。相比之下,选择性5-HT1B受体激动剂CP-93,129(3-(1,2,5,6-四氢吡啶-4-基)吡咯并[3,2-b]吡啶-5-酮)和5-HT1A受体选择性激动剂8-羟基-2-(二正丙基氨基)-四氢化萘(8-OH-DPAT)在静脉注射剂量高达3 mg kg(-1)时,在此试验中无作用。因此,可穿透脑屏障的曲坦类5-HT1B/1D受体激动剂在大鼠中可能通过5-HT1D受体介导其对三叉神经的中枢抗伤害性作用,而非通过5-HT1B或5-HT1A受体。